Full Press Release Details
Q3 Sales reach 150% of 1H Sales
Australia, April 6, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company
that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased
to announce the Q3 FY23 sales* results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan
Q3 YTD sales of Travelan and Protectyn increased by 239% in FY23 to AUD $1.46 M, compared to AUD $430
k for the corresponding period in FY22.
Australia, Travelan and Protectyn sales for Q3 were AUD $577 k, a 101% increase on sales for 1H FY23
(AUD $287 k). Australian Travelan and Protectyn Q3 YTD FY23 sales were AUD $864 k representing a
significant increase over the corresponding period in FY22 (AUD $80k). Travelan sales increase as overseas travel rebounds.
Australian resident short term departures in January 2023 were 80% of those in January 2019 (Australian Bureau of Statistics). Immuron
continues to restock wholesalers in line with increasing pharmacy sales.
American Travelan Q3 FY23 sales were AUD $298 k, greater than sales for 1H FY23 (AUD $297 k). North American Travelan
Q3 YTD FY23 sales were AUD $595 k, up by 70% on the corresponding period in FY22 (AUD $350 k). This growth was attributable to
increasing sales in both Passport Health Travel Clinics and distributor sales. While not at pre-pandemic peak, sales in the US are anticipated
to increase as Immuron replenishes and builds inventory.
is focused on growing sales of its commercial products, expanding its portfolio of products and has a strong existing pipeline.
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers' diarrhea.
In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers'
Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,
bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing
a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers' diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
more information visit: http://www.immuron.com
press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.